文献速递消化内镜

新型1L聚乙二醇肠道准备剂NER1006用于整体及右半结肠清洁:一项对比三硫酸盐的随机对照3期试验

Novel 1 L polyethylene glycol-based bowel preparation NER1006 for overall and right-sided colon cleansing: a randomized controlled phase 3 trial versus trisulfate.
PubMed 文献 · Gastrointest Endosc · 2017-08-10

这项随机、多中心、结肠镜医师与中心阅片者设盲的3期非劣效性试验,将621例结肠镜检查患者按1:1随机分配至NER1006组或三硫酸盐组,采用晚间/晨间分次给药。结果显示,NER1006在整体肠道清洁成功率(85.1% vs 85.0%)和升结肠/盲肠高质量清洁率(35.9% vs 29.3%)方面均非劣效于三硫酸盐。

要点

  • NER1006在整体肠道清洁成功率上非劣效于三硫酸盐(85.1% vs 85.0%)。
  • 升结肠/盲肠高质量清洁率NER1006为35.9%,三硫酸盐为29.3%,达到非劣效。
  • NER1006治疗相关不良事件发生率为14.9%,三硫酸盐为9.4%。

核心结论

  • 采用晚间/晨间分次给药时,NER1006在整体肠道清洁和右半结肠清洁方面与三硫酸盐同样有效。
  • NER1006的不良事件发生率略高于三硫酸盐,但未影响耐受性、依从性或疗效。

研究设计与样本

  • 随机、多中心、结肠镜医师与中心阅片者设盲的3期非劣效性试验。
  • 621例接受结肠镜检查的患者按1:1随机分配至NER1006组(n=310)或三硫酸盐组(n=311)。
  • 疗效评估人群共556例(NER1006组n=276,三硫酸盐组n=280)。
  • 采用经验证的Harefield清洁量表由设盲中心阅片者评估。
  • 非劣效界值为10%,显著性阈值为P < .025。

主要发现

  • 整体肠道清洁成功率:NER1006组85.1% vs 三硫酸盐组85.0%,差值0.14%,单侧97.5%置信下限-8.15%,P = .528。
  • 升结肠/盲肠高质量清洁率:NER1006组35.9% vs 三硫酸盐组29.3%,差值6.58%,置信下限-1.69%,P = .059。
  • 波士顿肠道准备量表(BBPS)评估结果支持整体肠道清洁成功率。
  • 两组的病变检出率相似。
  • 治疗相关不良事件发生率:NER1006组14.9% vs 三硫酸盐组9.4%。

关键数值与推荐

  • 整体肠道清洁成功率的非劣效性检验:NER1006组85.1% vs 三硫酸盐组85.0%,单侧97.5%置信下限-8.15%,P = .528。
  • 升结肠/盲肠高质量清洁率的非劣效性检验:NER1006组35.9% vs 三硫酸盐组29.3%,置信下限-1.69%,P = .059。
  • 非劣效界值为10%,显著性阈值为P < .025。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: NER1006 is the first 32 fluid ounce (1 L) polyethylene glycol-based bowel preparation. This randomized, multicenter, colonoscopist/central reader-blinded phase 3 non-inferiority trial assessed the efficacy, safety, and tolerability of NER1006 versus trisulfate for bowel cleansing. METHODS: Patients undergoing colonoscopy were randomized (1:1) to receive NER1006 or trisulfate, using evening/morning split-dosing administration. Blinded central readers used the validated Harefield Cleansing Scale to evaluate 2 alternative primary endpoints: overall bowel-cleansing success and high-quality cleansing of the ascending colon/cecum. Secondary endpoints included lesion detection, Boston Bowel Preparation Scale (BBPS) assessment, and adherence. The non-inferiority margin was 10% and the significance threshold was P < .025. RESULTS: Of 621 patients randomized (NER1006, n=310; trisulfate, n=311), 556 were evaluated for efficacy (NER1006, n=276; trisulfate, n=280). NER1006 achieved non-inferiority versus trisulfate for both primary endpoints of overall bowel-cleansing success (85.1% vs 85.0%; difference, 0.14%; one-sided 97.5% lower confidence limit [LCL], -8.15%; P = .528) and high-quality cleansing of the ascending colon/cecum (35.9% versus 29.3%; difference, 6.58%; LCL, -1.69%; P = .059). BBPS assessments supported overall bowel-cleansing success rates. Lesion detection rates were similar between the groups. The percentage of patients with treatment-related adverse events was 14.9% with NER1006 and 9.4% with trisulfate. Both bowel preparations showed similar overall tolerability and safety profiles. Adherence was very high in both arms. CONCLUSIONS: With evening/morning split dosing, NER1006 was as effective as trisulfate for overall bowel and right-sided colon cleansing. Adverse event rates were slightly higher with NER1006 than trisulfate, but did not compromise tolerability, adherence, or efficacy. (Clinical trial registration number: NCT02254486.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. DeMicco MP, Clayton LB, Pilot J, et al. Novel 1 L polyethylene glycol-based bowel preparation NER1006 for overall and right-sided colon cleansing: a randomized controlled phase 3 trial versus trisulfate. Gastrointest Endosc. 2017. PMID: 28803744. doi:10.1016/j.gie.2017.07.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。